Offer members evidence about medical technologies
It's not uncommon for bias and inaccuracies to infiltrate consumer health information and influence members' opinions about the healthcare they receive
With the array of new health technologies clamoring for attention from consumers and providers, the impact on managed care organizations can be significant as the costs associated with making wrong decisions continue to escalate. New and emerging technologies, even those approved for marketing, often have a limited evidence base with regard to their relative effectiveness and impact on clinical outcomes. Some are no more effective than competing technologies already in widespread clinical use; many are more expensive than existing options. Likewise, serious and life-threatening safety issues often don't emerge until after a new technology has been used by large numbers of patients over a longer period of time.
Conversations With Perry and Friends
April 14th 2025Perry Cohen, Pharm.D., a longtime member of the Managed Healthcare Executive editorial advisory board, is host of the Conversations with Perry and Friends podcast. His guest this episode is John Baackes, the former CEO of L.A. Care Health Plan.
Listen
Breaking Down Health Plans, HSAs, AI With Paul Fronstin of EBRI
November 19th 2024Featured in this latest episode of Tuning In to the C-Suite podcast is Paul Fronstin, director of health benefits research at EBRI, who shed light on the evolving landscape of health benefits with editors of Managed Healthcare Executive.
Listen
Phase 3 Trial of Vertex’s Islet Cell Therapy for Type 1 Diabetes Under Way
April 23rd 2025Zimislecel is an allogeneic stem cell-derived islet cell therapy that could eliminate the need for insulin in those who have type 1 diabetes. Regulatory submissions are expected in 2026, and if approved, would be the second cell therapy for type 1 diabetes.
Read More
